Skip to content
2000
Volume 21, Issue 1
  • ISSN: 1573-4080
  • E-ISSN: 1875-6662

Abstract

Background

The present study highlights the comparative therapeutic efficacy of the newly synthesized drug 17-Oximino-5-androsten-3β-yl 4-aminobenzoate (17a-aza steroid) and finasteride for the treatment of experimentally induced prostate carcinogenesis in rats. Considering the inhibitory activity of the oximes to 5α-reductase and the role of the ester group in augmenting the anti-androgenic property, we decided to synthesize a compound with a lactam moiety in ring D and esters at 3β position of androsterone nucleus as a more potent 5α-reductase inhibitor.

Methods

In this study, 30 Sprague Dawley (SD) rats were divided into six groups, . Group I as normal controls, Group II was treated with carcinogen -methyl--nitrosourea (MNU) and hormone testosterone propionate (TP) for inducing prostate cancer, Group III rats were treated with finasteride (10 mg/Kg of body weight for 8 weeks through oral gavage), Group IV was treated with 17a-aza steroid (10 mg/Kg of body weight for 8 weeks through oral gavage), whereas, Group V and Group VI were given finasteride and 17a-aza steroid, respectively, with similar doses as in Group III and IV after pretreatment with a carcinogen (MNU) and hormone (TP).

Results

The induction of carcinogenesis by treating animals with MNU+TP revealed a significant reduction in weight loss as compared to the normal control group, which, however, increased following 17a-aza steroid treatment. Furthermore, the study witnessed a significant improvement in prostatic biomarker, prostatic acid phosphatase (PAcP) in serum following finasteride and 17a-aza steroid treatment to MNU+TP treated rats. Histological investigation of prostate tissue sections of 17a-aza steroid-treated prostate cancer rats showed milder hyperplastic glandular epithelium and exhibited signs of recovery as compared to carcinogen-treated rats.

Conclusion

The present findings are preliminary and suggest that the 17a-aza steroid has therapeutic efficacy for the management of experimentally induced prostate cancer, as evidenced by changes in prostate weight, PAcP levels, and histology. In comparison to finasteride, further exploration is needed to assertively conclude its comparative therapeutic efficacy.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cei/10.2174/0115734080317716240930071759
2024-10-14
2025-11-05

  • From This Site

    /content/journals/cei/10.2174/0115734080317716240930071759
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.21492 30207593
     [Google Scholar]
  2. NacusiL.P. TindallD.J. Targeting 5α-reductase for prostate cancer prevention and treatment.Nat. Rev. Urol.20118737838410.1038/nrurol.2011.67 21629218
     [Google Scholar]
  3. NacusiL.P. TindallD.J. Androgen receptor abnormalities in castration-recurrent prostate cancer.Expert Rev. Endocrinol. Metab.20094541742210.1586/eem.09.34 20228873
     [Google Scholar]
  4. LangeC.A. GioeliD. HammesS.R. MarkerP.C. Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer.Annu. Rev. Physiol.200769117119910.1146/annurev.physiol.69.031905.160319 17037979
     [Google Scholar]
  5. PoutanenM. Hagberg ThulinM. HärkönenP. Targeting sex steroid biosynthesis for breast and prostate cancer therapy.Nat. Rev. Cancer2023231068670910.1038/s41568‑023‑00609‑y 37684402
     [Google Scholar]
  6. RussellD.W. WilsonJ.D. Steroid 5α-reductase: Two genes/two enzymes.Annu. Rev. Biochem.1994631256110.1146/annurev.bi.63.070194.000325 7979239
     [Google Scholar]
  7. LabrieF. Adrenal androgens and intracrinology.Semin. Reprod. Med.200422429930910.1055/s‑2004‑861547 15635498
     [Google Scholar]
  8. AndrioleG. BruchovskyN. ChungL.W. Dihydrotestosterone and the prostate: The scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.J. Urol.20041724 Pt 11399140310.1097/01.ju.0000139539.94828.29 15371854
     [Google Scholar]
  9. ImamotoT. SuzukiH. YanoM. The role of testosterone in the pathogenesis of prostate cancer.Int. J. Urol.200815647248010.1111/j.1442‑2042.2008.02074.x 18430151
     [Google Scholar]
  10. PrestonM.A. WilsonK.M. MarktS.C. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.JAMA Intern. Med.201417481301130710.1001/jamainternmed.2014.1600 24887392
     [Google Scholar]
  11. JanG. BhatS. ChauhanM. DhawanD.K. DhingraN. ChadhaV.D. Target specific uptake of a newly synthesized radiolabeled 5α-reductase inhibitor “tc-99m-17-oxo-17a-aza-d-homo-5-androsten-3β-yl phenoxyacetate (tc-99m-17a-aza steroid)” in rat prostatic neoplastic lesions.Indian J. Nucl. Med.202237213314110.4103/ijnm.ijnm_128_21 35982808
     [Google Scholar]
  12. DhingraN. BhardwajT.R. MehtaN. MukhopadhyayT. KumarA. KumarM. Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.Eur. J. Med. Chem.20104562229223610.1016/j.ejmech.2010.01.064 20171759
     [Google Scholar]
  13. JanG. PassiN.D. DhawanD.K. ChadhaV.D. Cancer targeting potential of 99mtc-finasteride in experimental model of prostate carcinogenesis.Cancer Biother. Radiopharm.2017322394710.1089/cbr.2016.2032 28301260
     [Google Scholar]
  14. SharmilaG. AthiraiT. KiruthigaB. Chemopreventive effect of quercetin in MNU and testosterone induced prostate cancer of Sprague-Dawley rats.Nutr. Cancer2014661384610.1080/01635581.2014.847967 24320139
     [Google Scholar]
  15. ArunkumarA. VijayababuM.R. VenkataramanP. SenthilkumarK. ArunakaranJ. Chemoprevention of rat prostate carcinogenesis by diallyl disulfide, an organosulfur compound of garlic.Biol. Pharm. Bull.200629237537910.1248/bpb.29.375 16462049
     [Google Scholar]
  16. BoslandM.C. SchlichtM.J. HortonL. McCormickD.L. The MNU plus testosterone rat model of prostate carcinogenesis.Toxicol. Pathol.202250447849610.1177/01926233221096345 35588266
     [Google Scholar]
  17. TenniswoodM. BirdC.E. ClarkA.F. Acid phosphatases: Androgen dependent markers of rat prostate.Can. J. Biochem.197654435035710.1139/o76‑051 1268758
     [Google Scholar]
  18. LuckH. Catalase. Methods of enzymatic analysis, HU Bergmeyer, aditor197188593
     [Google Scholar]
  19. KonoY. Generation of superoxide radical during auto oxidation of hydroxylamine and an assay of superoxide dismutase.Arch. Biochem. Biophys.1978186189195
     [Google Scholar]
  20. EllmanG.L. Tissue sulfhydryl groups.Arch. Biochem. Biophys.1959821707710.1016/0003‑9861(59)90090‑6 13650640
     [Google Scholar]
  21. WillsE.D. Mechanisms of lipid peroxide formation in animal tissues.Biochem. J.196699366767610.1042/bj0990667 5964963
     [Google Scholar]
  22. DavidL. Chemoprevention of rat prostate carcinogenesis by dietary 16a-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosteron.Carcinogenesis2007282398403 16952912
     [Google Scholar]
  23. HarrisW.P. MostaghelE.A. NelsonP.S. MontgomeryB. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion.Nat. Clin. Pract. Urol.200962768510.1038/ncpuro1296 19198621
     [Google Scholar]
  24. PerlmutterM.A. LeporH. Androgen deprivation therapy in the treatment of advanced prostate cancer.Rev. Urol.20079Suppl. 1S3S8
     [Google Scholar]
  25. ChenY. LinP.H. FreedlandS.J. ChiJ.T. Metabolic response to androgen deprivation therapy of prostate cancer.Cancers20241611199110.3390/cancers16111991 38893112
     [Google Scholar]
/content/journals/cei/10.2174/0115734080317716240930071759
Loading
Therapeutic Potential of 5α-Reductase Inhibitor 17-oxo-17a-aza-D-homo-5-androsten-3β-yl phenoxyacetate (17a-aza Steroid) in the Management of Prostate Cancer
Curr. Enzym. Inhib. 21, 52 (2025); https://doi.org/10.2174/0115734080317716240930071759
/content/journals/cei/10.2174/0115734080317716240930071759
/content/journals/cei/10.2174/0115734080317716240930071759
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): 17a-aza steroid; 5α-reductase; adenocarcinoma; finasteride; prostate carcinogenesis; prostatic acid phosphatase; prostatic intraepithelial neoplasia

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test